Literature DB >> 7902973

Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide.

A Clements1, D M Walsh, C H Williams, D Allsop.   

Abstract

We assessed the fibrillogenic properties of synthetic peptides corresponding to residues 13-26 of beta/A4 amyloid, containing either the normal sequence (beta 13 26) or the mutations Glu22 to Gln (beta 13-26Q22) and Ala21 to Gly (beta 13-26G21). The kinetics of aggregation were monitored at 37 degrees C and pH 7.4 by measuring the amount of peptide remaining in solution, using reverse-phase high performance liquid chromatography. Negative stain electron microscopy revealed that all of the peptides formed fibrils. However, beta 13-26Q22 showed greatly accelerated fibril formation compared to the other two. The results suggest that the Q22 mutation confers increased amyloidogenic properties on the beta/A4 peptide, whereas the G21 mutation acts by a different pathogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902973     DOI: 10.1016/0304-3940(93)90129-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

1.  Point mutations in Aβ induce polymorphic aggregates at liquid/solid interfaces.

Authors:  Elizabeth A Yates; Elena M Cucco; Justin Legleiter
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

2.  Lipid-induced conformational transition of amyloid beta peptide fragments.

Authors:  Nagarajan Sureshbabu; R Kirubagaran; H Thangarajah; E J Padma Malar; R Jayakumar
Journal:  J Mol Neurosci       Date:  2010-05-18       Impact factor: 3.444

3.  Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

Authors:  D J Watson; D J Selkoe; D B Teplow
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

4.  In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease.

Authors:  D M Walsh; D M Hartley; M M Condron; D J Selkoe; D B Teplow
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

Review 5.  The toxicity in vitro of beta-amyloid protein.

Authors:  L L Iversen; R J Mortishire-Smith; S J Pollack; M S Shearman
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

6.  The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis.

Authors:  C Soto; E M Castaño
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

7.  Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.

Authors:  Samir Kumar-Singh; Patrick Cras; Rong Wang; John M Kros; Johan van Swieten; Ursula Lübke; Chantal Ceuterick; Sally Serneels; Krist'l Vennekens; Jean-Pierre Timmermans; Eric Van Marck; Jean-Jacques Martin; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin.

Authors:  Vicki Betts; Malcolm A Leissring; Georgia Dolios; Rong Wang; Dennis J Selkoe; Dominic M Walsh
Journal:  Neurobiol Dis       Date:  2008-06-17       Impact factor: 5.996

Review 10.  Unifying features of systemic and cerebral amyloidosis.

Authors:  J Ghiso; T Wisniewski; B Frangione
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.